"Not Valproic Acid" Is Not Without Risk: In Utero Exposure to Topiramate Is Associated With an Increased Risk of Neurodevelopmental Disorders
- PMID: 36923329
- PMCID: PMC10009118
- DOI: 10.1177/15357597221130878
"Not Valproic Acid" Is Not Without Risk: In Utero Exposure to Topiramate Is Associated With an Increased Risk of Neurodevelopmental Disorders
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Comment on
-
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability.JAMA Neurol. 2022 Jul 1;79(7):672-681. doi: 10.1001/jamaneurol.2022.1269. JAMA Neurol. 2022. PMID: 35639399
References
-
- Hernández-Díaz S, McElrath TF, Pennell PB, Hauser WA, Yerby M, Holmes LB. Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol. 2017;82(3):457–465. doi:10.1002/ana.25031 - PubMed
-
- Rihtman T, Parush S, Ornoy A. Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod Toxicol. 2012;34(3):308–311. doi:10.1016/j.reprotox.2012.05.038 - PubMed
-
- Bromley RL, Calderbank R, Cheyne CP, et al. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 2016;87(18):1943–1953. doi:10.1212/WNL.0000000000003157 - PubMed
-
- Bech LF, Polcwiartek C, Kragholm K, et al. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. J Neurol Neurosurg Psychiatry. 2018;89(12):1324–1331. doi:10.1136/jnnp-2018-318386 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
